Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
THBS1 Is a Novel Serum Prognostic Factors of Acute Myeloid Leukemia
29 Pages Posted: 11 Jun 2019
More...Abstract
Background: Dysregulation of cytokines and growth factor is a general hallmark of AML patients, unraveling the mysteries of cytokine and growth factor interaction in the context of AML is of utmost importance. Here, we evaluated bone cytokines profiling in bone marrow serum sample in AML patients and healthy controls.
Methods: Serum expression profiles of 507 proteins in the serum samples of 14 patients (9 AML patients and 5 healthy controls) using RayBiotech biotinylated antibody chip. THBS1 expression in 116 patients and nine healthy control was verified via ELISA.
Findings: Compared with healthy people, 31 signature proteins were found to be significantly expressed in AML patients, among these proteins, 27 proteins were highly expressed. When divided into well prognosis and poor prognosis, 12 signature proteins were significantly and differently expressed. Furthermore, in order to identify the results of expression profiles, we verified and analysis the expression of THBS1 (Thrombospondin 1) in the 116 patients and nine healthy control. We found that THBS1 was lowly expressed in AML patients, patients with low expressed THBS1 possessed shorter survivor time, and promoter methylation was the cause of the low expression of THBS1.
Interpretation: Our data indicated that RayBiotech biotinylated antibody chip analysis can unveil differentially expressed proteins in AML patients, and THBS1 may be a novel therapeutic approach for AML patients.
Funding: Supported by grants from the National Natural Science Fund for Youth (No. 81600166)
Declaration of Interest: All authors declare no competing interests.
Ethical Approval: This study was approved by the Xinqiao hospital Ethics committees and all patients provided a signed informed consent. All human specimens used in the experiments were approved by Ethics committee of Army Medical University.
Keywords: Acute myeloid leukemia, Protein microarray, serum protein markers, THBS1, promoter methylation
Suggested Citation: Suggested Citation